Subscribe To
NLTX / Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript
NLTX News
By GuruFocus
July 27, 2023
Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc
San Francisco-based investment firm, Redmile Group, LLC (Trades, Portfolio), recently increased its holdings in Neoleukin Therapeutics Inc ( NLTX , Fi more_horizontal
By Seeking Alpha
April 19, 2023
Neoleukin Therapeutics: Strategic Review Play
Neoleukin Therapeutics: Strategic Review Play more_horizontal
By Zacks Investment Research
March 10, 2023
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan
Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of more_horizontal
By GeekWire
March 9, 2023
Shares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or merger
Neoleukin Therapeutics is slashing its workforce by about 70% as it seeks “strategic alternatives” for its future, according to a company statemen more_horizontal
By Seeking Alpha
August 10, 2022
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call Transcript
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Julie Rathbun - Investor R more_horizontal
By GlobeNewsWire
April 7, 2022
Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophist more_horizontal
By Seeking Alpha
March 1, 2022
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Seeking Alpha
March 1, 2022
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript more_horizontal